Bernice Downey

Dr. Bernice Downey is a woman of Ojibwe and Celtic heritage, a mother and a grandmother. She is a medical anthropologist with research interests in health, health literacy and Indigenous Traditional knowledge and health/research system reform for Indigenous populations. Bernice is currently cross appointed to the School of Nursing and Department of Psychiatry and Neuro-Behavioural Sciences and is the IndigenousHealth Lead for the Faculty of Health Science at McMaster University. This past year she successfully led the development of the McMaster Indigenous Research Institute.

She is also the Regional Aboriginal Cancer Lead for Cancer Care Ontario, Toronto-Central Region.

Bernice’s professional experience includes Sole Proprietor of her consulting company: "Minoayawin - Good Health Consulting"; Chief Executive Officer of the National Aboriginal Health Organization, Executive Director of the Aboriginal Nurses Association of Canada, Associate Director and Research Associate of the Well Living House -Centre for Research on Inner City Health at St. Michael’s Hospital in Toronto. She was a member of the Canadian Institute of Health Research - Institute of Aboriginal Health,Advisory Board for six years. She was appointed to the WHO Commission on the Social Determinants of Health, Canadian Reference Group. She is an experienced administrator, facilitator, and an organizational and systemic change agent. She is also a life - long advocate in the work towards addressing the serious health inequities among Indigenous populations in Canada.

David O'Neill

Dr. David O’Neill joined FACIT in 2013 and is responsible for start-up company corporate strategy and pharmaceutical partnerships. He brings a wealth of networks and experience as an Advisor to FACIT investee companies including Fluorinov Pharma (Trillium Therapeutics), Novera Therapeutics and Turnstone Biologics. Previously, Dr. O’Neill held roles of increasing responsibility during his eight years with Ambit Biosciences (Daiichi Sankyo), including Project Leader for Quizartinib; non-clinical safety programs in oncology and inflammation, IND preparation, project and risk management and program strategy. With the Business Development team, he conducted compound licensing, Alliance Management, Discovery collaborations and marketing kinase profiling (KinomeScan, acquired by DiscoveRx) services and technology. Prior to Ambit, Dr. O’Neill served as Research Liaison at AstraZeneca on behalf of Global Discovery Alliances, with a focus on in-licensing technologies and compounds from researchers and biotechnology companies, as well as competitive intelligence and Alliance Management. Dr. O’Neill holds a PhD from the University of Western Ontario from the Faculty of Health Sciences.

Donna Wall

Dr. Wall joined SickKids/University of Toronto in the fall of 2016 as Section Head of the Blood and Marrow Transplant/Cellular Therapy program. After completing paediatric and paediatric hematology/oncology training in New York and Boston she went on to establish BMT and public cord blood banks in St. Louis and San Antonio. Most recently she has led the Manitoba Blood and Marrow Transplant program. She has chaired the hematopoietic stem cell transplant discipline in the Children's Oncology Group and has had leadership positions in the Paediatric Blood and Marrow Transplant Group, the Canadian Blood and Marrow Transplant Group and the CIHR-funded Canadian National Transplant Research program. Her research has focused on improving the outcomes of children undergoing transplant through a better understanding of the role of the innate immune system in transplantation and the interaction between donor immune cells and their new environment as tolerance is established and as a tool to treat leukemia.

Elizabeth Eisenhauer

Dr. Eisenhauer obtained her MD from Queen’s University Kingston, Canada in 1976 and subsequently received fellowships in Internal Medicine and Hematology from the Royal College of Physicians and Surgeons Canada. She is currently a Professor in the Departments of Oncology and Medicine at Queen’s and since 2012 she has been Head, Department of Oncology at Queen’s University and Cancer Program Medical Director at Kingston General Hospital in Kingston.

From 1982 to 2012, she was Director of the Investigational New Drug Program of the NCIC Clinical Trials Group where her major responsibilities lay in identifying and bringing into clinical trial novel cancer agents. Her major research interest has been the evaluation of new anti-cancer agents. She has coordinated over 170 phase I, II and III trials which have been carried out in institutions in Canada, the US and Europe. Several of these trials have led to the identification of new cancer agents now used in clinical practice. She also served as Interim Director of NCIC Clinical Trials Group from 2013-2014. In addition, she held the role of Research Lead for the Canadian Partnership Against Cancer and Co-Chair of the Canadian Cancer Research Alliance from 2007-2017.

She has been active on a number of committees of the American Society of Clinical Oncology (Board of Directors), the American Association of Cancer Research, the European Society of Medical Oncology and the European Organization for Research and Treatment of Cancer (Scientific Audit Committee) and the Canadian Cancer Society. From 2006-2009 she served as President, National Cancer Institute of Canada.

She has been awarded the O. Harold Warwick Prize of the National Cancer Institute of Canada (now Canadian Cancer Society) that recognizes a scientist whose research has had a major impact in Cancer Control in Canada, the Society of Gynecologic Oncology of Canada (GOC) Presidential Medal Award in recognition of her outstanding contributions to gynecologic oncology in Canada and abroad, and the Queen Elizabeth II Diamond Jubilee medal for “tremendous commitment to the advancement of cancer therapy, supportive care and prevention across Canada and internationally”.  In 2015 she was elected a Fellow of the Royal Society of Canada, one of the highest honours for Canadian academics in the arts, humanities, and sciences.

Erin M. Siegel

Dr. Siegel is the Scientific Director of Total Cancer Care at the H. Lee Moffitt Cancer Center and Research Institute and Assistant Professor in the Department of Oncologic Sciences, University of South Florida. She is a Molecular Epidemiologist with over 10 years of experience leading epidemiological studies focused on cervical, anal and colorectal cancers, with over 50 peer reviewed publications and active NIH funding in colorectal and anal cancer.

Her research expertise spans cancer outcomes research, gene expression and methylation profiles, and molecular epidemiological studies focused on HPV in relation to cervical and anal cancer. As Scientific Director of Total Cancer Care, she is the operational leader of Moffitt's Total Cancer Care protocol, the Program Manager of ORIEN at Moffitt, and contributes to the scientific leadership of the Moffitt’s enterprise-wide data warehouse.

Hans Messner

Dr. Messner trained as a physician in Ulm, Germany, and went on to do a Ph.D., at University of Toronto. He has worked for over 40 years in the field of bone marrow transplantation. Dr. Messner directs the clinical Bone Marrow Transplant (BMT) program. He is beloved and respected by his peers and patients. As a 'founding father' of bone marrow and stem cell transplantation, Dr. Messner has not only extended the lives of thousands of blood cancer patients, but he has given them a higher quality of life while dealing with the disease. He is also a proud participant in the RTCC.

Jasmine Grant

Jasmine Grant is the Education Lead for the Cancer Clinical Research Unit within Princess Margaret Cancer Program. She is responsible for writing, developing and facilitating training programs based on clinical research staff needs and audit findings. Her projects include the standardization of clinical research processes and managing the administration of the CCRU Elearning platform for Princess Margaret Cancer Centre. Jasmine also has experience working as a Clinical Study Coordinator, monitoring and coordinating multicentre clinical oncology trials at The Princess Margaret since 2006.  In 2013 she completed her Master's degree in Adult Education and Community Development at the Ontario Institute for Studies in Education at the University of Toronto. Prior to this, Jasmine graduated from the University of Western Ontario with a Bachelor of Health Science with an Honours specialization in Health Promotion. She is an active member of SoCRA and a graduate from the Clinical Research Graduate Certification Program at Humber College. As of 2017, Jasmine is a faculty member teaching within Seneca College’s Clinical Research and Regulatory Affairs program.

Jean-Francois Pouliot

Dr. Jean-Francois Pouliot obtained his doctorate in human physiology at the faculty of medicine at the University of Montreal. After completing a post-doctoral training at McGill University where he worked on multidrug resistance reversing agents in cancer; Dr. Pouliot joined the pharmaceutical industry where he assumed several leadership roles in Clinical Research and Development. During his career he worked on several major registration programs in Breast Cancer, Bone Metastasis, Leukemia, Glioblastoma Multiform and Immunotherapy. Currently back in North America from a position in Europe as Regional Director of Medical Affairs for Europe and Canada, he is the International Medical Lead- Oncology.

Jessie Miller

Jessie Miller obtained a Bachelor of Science, with honours, from the University of Western Ontario followed by the completion of the Clinical Research Program at Humber College. Jessie completed the Leadership Program from the University of Toronto in 2015. Jessie was recruited to Ozmosis Research Inc. in 2007 as a Clinical Trials Specialist where she managed multi-centre Phase I-III oncology clinical trials. Jessie held progressive roles at Ozmosis Research Inc. covering full service clinical trial management, vendor management, clinical operations, and business development. She has overseen the SOP Committee since 2009 and led Ozmosis’ Accreditation in a data management system in 2014. In her current role as Director of Clinical Operations, she is actively involved in all aspects of clinical operations, data management, and business development. Jessie holds a Certified Clinical Research Professional designation and is a member of SoCRA and DIA.

Kate Niehaus

Kate Niehaus is originally from Corning, New York, but has lived in the New York metro area with her husband, Bob, for all of her adult life. She had a career as a full-time mom to their three children until several years ago when her youngest child started college. Since then she has been actively involved as a patient advisor at Memorial Sloan Kettering Cancer Center, serving as a Patient-to-Patient volunteer and as a member of the hospital Ethics and Quality Assessment Committees. Kate is a cancer survivor and is proud of MSK's new Robert and Kate Niehaus Center for Inherited Cancer Genomics which uses the latest in gene sequencing technologies to discover the inherited causes of cancer. The ultimate goal is to develop new approaches for prevention as well as earlier detection and treatment of cancer.

Kristina K. Hardy

Dr. Hardy is a pediatric neuropsychologist within the Neuropsychology Division at Children's National Health System (CNHS) in Washington, DC. Dr. Hardy's clinical practice centers on evaluating and treating children with neurodevelopmental and acquired difficulties with learning, memory, and executive functioning. Her federally-funded clinical research program is focused primarily on identifying factors associated with neurocognitive difficulties in survivors of pediatric cancer and children with neurofibromatosis, as well as developing and evaluating interventions for these difficulties. She has a particular interest in evaluating the use of technology in the context of neuropsychological health, including computerized assessment and cognitive training programs. Dr. Hardy is also involved with planning and conducting clinical studies associated with the Children’s Oncology Group, in which she serves as Vice-Chair of the Behavioral Science and Neurotoxicity committees. At CNHS, Dr. Hardy serves as the Director for the Neuropsychological and Psychosocial Evaluation Core of the Clinical Studies Resource within the Clinical and Translational Science Institute, and is actively involved in training students at all levels.

Leslie Fedorak

Leslie Fedorak is the Manager of the Clinical Trials Unit at the Cross Cancer Institute in Edmonton. Leslie has worked as an oncology nurse at the Cross Cancer Institute for the past 25 years in various nursing positions. Prior to taking over the management of the Clinical Trial Unit, Leslie was the Melanoma Research Nurse for 14 years.

Maria Schlag

Maria Schlag has been working at Princess Margaret Cancer Centre since 2008. Maria has been in her current role as Manager of the Clinical Trials Support Unit since 2015. In this role she manages research staff and a portfolio of over 100 active clinical trials and research studies. She is also a member of the Volunteer Audit and Monitoring Committee for the Canadian Cancer Trials Group. Before joining The Princess Margaret Maria worked as a Senior Regulatory Operations Associate for Bayer, both in Toronto and Germany. She received a Bachelor of Science in Pharmacy from Freie Universitaet in Berlin. Maria holds a Certified Clinical Research Professional designation and is a member of SoCRA.

Mark Minden

Dr. Minden is a Professor at University of Toronto, Department of Medical Biophysics. He holds an MD, PhD and is a medical oncologist and senior scientist working with the leukemia group at Princess Margaret Cancer Centre. Dr Minden has many publications in leading journals and is extensively involved in clinical trials. His research interests include the identification of genes involved in chromosomal translocations and the growth and regulation of acute myeloblastic leukemia (AML) cells. Since 1976 Dr. Minden has been involved in the procurement, storage and distribution of viable leukemic cells to collaborators at the Princess Margaret, in Toronto, and around the world.

Michael F. Brady

Have you ever wondered what it takes to survive a terminal diagnosis of cancer? Mike knows. He has lived a cancer journey that has spanned a decade from first diagnosis of a chronic blood cancer to the fateful transformation to one of the rarest forms of blood cancer – Post Polycythemia Myelofibrosis.  Mike obtained the radical cure by combining his healing focus with the first of a kind innovative stem cell transplant, performed by the Princess Margaret Cancer Centre.   During this journey Mike grew a beautiful family, amazing career & developed a methodology for achieving health success that inspires patients, medical researchers, fundraisers, doctors, nurses and the average person to aspire for excellence in their pursuits to achieve health success…for themselves and others.

Mike holds a Professional Engineering License, a Bachelor of Engineering Science from the University of Western Ontario and an MBA from the Richard Ivey School of Business. Mr. Brady is a member of the Canadian Cancer Society’s Nominating and Governance Committee (On.), Board Member for the Canadian MPN Network, and Vice Chairperson of the Canadian MPN Research Foundation.

Mr. Brady’s professional career spans 20 years having been employed by major Canadian energy corporations.  He is currently co-CEO and Cofounder of Frederick & Simon Inc., a professional sales & promotion consultant firm focused on assisting clients develop new global markets through direct sales & market representation and by helping clients optimize sales functions and client relations. His executive leadership functions have included sales & marketing, general management, government relation, merger & acquisition and business development.

Mr. Brady lived and worked in Europe on behalf of former employers and has travelled extensively in the Americas, EU and MENA countries for work and pleasure.

Pamela Degendorfer

Ms. Degendorfer is the Program Director for the Cancer Clinical Research Unit (CCRU) at the Princess Margaret Cancer Centre. 

After graduating with a Master’s Degree from the University of Toronto, Ms. Degendorfer

began her career at Princess Margaret in 1987. She was recruited to the Drug Development Program in 2001 where she was appointed Manager of the Robert & Maggie Bras and Family New Drug Development Program (DDP) helping build the program into the largest cancer drug development program in Canada. The DDP held an N01 contract through the NCI for many years and is an ETCTN member.  Ms Degendorfer has worked extensively with CTEP trials and managed a consortium of sites as part of the N01.

As Program Director since 2009, Ms Degendorfer guides the operations and strategic direction of the CCRU and clinical research across the Princess Margaret.  CCRU is seen as a clinical research leader in Canada; steering, developing and working with teams in QA, education, finance, trial operations, correlative studies, trials nursing, biostats, and metrics. Ms Degendorfer is also Chief Operating Officer at Ozmosis Research, a social enterprise company that manages oncology clinical trials both nationally and internationally.  Profits from Ozmosis Research may be directed by the Board towards oncology clinical research at the Princess Margaret.

She has been an expert consultant for academic cancer centres in Canada and abroad. Working with a variety of sponsors including pharmaceutical companies, biotechnology companies and the National Cancer Institute in both the United States and Canada has given Ms. Degendorfer a wide breadth of experience in clinical trials management.

Penelope Bradbury

Dr. Bradbury is a medical oncologist, Associate Professor, Department of Medicine, University of Toronto, and adjunct Associate Professor within the Department of Oncology at Queen’s University, and held a Cancer Care Ontario Research Chair in Experimental Therapeutics. She is a graduate of Cardiff University Medical School, UK. She undertook specialist medical oncology training at the MidCentral Regional Cancer Treatment Service in New Zealand, and at the Cancer Research UK Medical Oncology Department, Churchill Hospital, Oxford, UK, obtaining the FRACP in 2005. She undertook fellowship training in thoracic oncology at Princess Margaret Cancer Centre, Toronto, and a one year drug development fellowship with the Canadian Cancer Trials Group (CCTG), as part of The Terry Fox Foundation Training Program in Transdisciplinary Cancer Research at Canadian Institutes of Health Research. Following which, she worked as a senior investigator for the thoracic oncology disease site, sarcoma disease site and investigational new drugs program within the CCTG, gaining leadership experience in the conduct of phase I-III national and international clinical trials. She is currently working as a staff physician at Princess Margaret Cancer Centre in the thoracic and sarcoma disease sites. She has a research interest in the evaluation of new therapies for the management of thoracic malignancies and clinical trial methodology.

Rajat Kumar

Dr. Rajat Kumar graduated from Maulana Azad Medical College, and completed his residency in Internal Medicine in 1981 from the faculty of Medicine, Delhi University. He then served in the Armed Forces Medical Services of India for 21 years, during which time he was trained for two years in clinical Haematology at Guy's hospital, London, UK. He then taught in the department of Medicine, Armed Forces Medical College, Pune. Later, he started a blood and marrow transplantation (BMT) center in Army Hospital R&R, Delhi. In 2003 he was selected as Professor of Haematology, All India Institute of Medical Sciences (AIIMS) where he also started a BMT program.

In April 2008, Dr. Kumar was recruited to CancerCare Manitoba (CCMB), as a haemato-oncologist and Professor at the University of Manitoba, and received academic certification from the Royal College in 2008. His outpatient clinical practice includes patients of MDS, lymphomas and leukemias and he has chaired the lymphoproliferative disease site group. He provides in-patient service to the leukemia/BMT ward. He completed an MSc in Health Economics, Policy and Management from the London School of Economics, UK, in 2012. Dr. Kumar is Medical Director of the Clinical Investigations Office and Chair of standards committee of CancerCare Manitoba. The Royal College of Physicians and Surgeons of Canada have selected Dr. Rajat Kumar as the recipient of the 2013 Manitoba/Saskatchewan region Prix d'excellence/Specialist of the Year award.

Richard McClelland

Richard McClelland is the Operations Lead for the Clinical Cancer Research Unit at the London Regional Cancer Program. He is responsible for managing a team of clinical research associates to ensure clinical trials and research projects are conducted in a transparent, safe, efficient and sustainable fashion.

Robert Kridel

Dr. Kridel went to medical school in Brussels, Belgium, and obtained Swiss Board Certification in Medical Oncology following residency training in Geneva, Switzerland. He then moved to Vancouver to pursue a PhD under the supervision of Dr. Randy Gascoyne, which he completed in 2016. Dr. Kridel did his lymphoma fellowship at the BC Cancer Agency under the supervision of Dr. Laurie Sehn. Since 2017, Dr. Kridel is a Staff Physician and Affiliate Scientist in the Lymphoma Group at the Princess Margaret Cancer Centre. His research interests include lymphoma genomics and how they correlate with treatment response.

Susan Marlin

Susan Marlin is the President and CEO of Clinical Trials Ontario (CTO), an organization established by the Province of Ontario in 2012 to help Ontario become a preferred location for global clinical trials while maintaining the highest ethical standards. Susan led the establishment of the CTO and the implementation of a province-wide streamlined research ethics review system. Prior to serving in this position she spent a decade working in research administration at Queen`s University, most recently serving as the Associate Vice-Principal of Research. Before this Susan worked with the National Cancer Institute of Canada Clinical Trials Group for many years, initially coordinating cancer clinical trials and later leading the development and implementation of the Ethics and Regulatory Office.

Susan has been actively engaged in research ethics over the years and has served on several research ethics committees. She served as President of the Canadian Association of Research Ethics Boards, as a member of the Canadian Institutes of Health Research (CIHR) Research Integrity Committee, the Ontario Cancer Research Ethics Board and the Tri-Agency Panel on the Responsible Conduct of Research. Susan serves on several boards and committees supporting clinical research and innovation in health care including the Life Sciences Ontario, the National Advisory Group for the Canadian Clinical Trials Coordinating Centre, and the Management Team for the Ontario SPOR (Strategy for Patient Oriented Research) Support Unit.
Susan was born and raised in Halifax, Nova Scotia. She holds a BSc (Hons) from Dalhousie University, and an MSc in Community Health and Epidemiology from Queen’s University. She was awarded the Queen’s Elizabeth II Diamond Jubilee medal in 2012 in recognition of her work in support of military and veteran health research.

Suzanne Trudel

Dr. Trudel received her medical degree from the University of Toronto. Her training included postdoctoral fellowships at the University of Toronto and Weill Medical College at Cornell University. In addition to her position as Associate Professor of Medicine at the University of Toronto, she is a clinician investigator at Princess Margaret Cancer Center, a Faculty Member of the Department of Medical Biophysics and an Affiliate scientist at Ontario Cancer Institute.

Dr. Trudel is certified in internal medicine and hematology, and she is an active member of several professional organizations. For the Multiple Myeloma Research Consortium (MMRC), Dr. Trudel is a present is member of the Steering Committee of this international organization. She is a member of the advisory Boards for Myeloma Canada and the Multiple Myeloma Translational Initiative, University of California San Franciso (USCF) and is a member of the Subcommitte on Correlative Sciences for National Cancer Institute of Canada Clinical Trials Group. For the American Society of Hematology (ASH), Dr Trudel has formerly served as a member of the Ad Hoc Scientific Committee on Plasma Cell Biology and has previously been the recipient of an ASH Scholar Award.

An active researcher, Dr. Trudel has been a principal investigator on several funded investigator initiated clinical trials for relapsed multiple myeloma including an NIH/Cancer Therapeutic Evaluation Program (CTEP) sponsored study. Her research focus has been in the areas of precision medicine for multiple myeloma. This encompasses three main interconnected themes 1) identification and validation of new therapeutic targets, 2) Phase I/II clinical trials of precision based therapies and 3) identification of biomarkers and development of novel platforms to support clinical trials of personalized medicine. Dr. Trudel's research has been supported by major organizations, including the Canadian Institutes of Health Research, the American Society of Hematology, the Multiple Myeloma Research Foundation, the Ontario Institute for Cancer Research, the Leukemia and Lymphoma Society, Myeloma Canada, the Canadian Cancer Society for Research Institute and the Terry Fox Research Institute. Her work has been published in numerous referenced journals, including Blood, Clinical Cancer Research, the Journal of Clinical Oncology and Nature Communications.